Literature DB >> 14962785

Laboratory-acquired vaccinia infection.

Clifford G Wlodaver1, Gregory J Palumbo, Joseph L Waner.   

Abstract

BACKGROUND: Complications following vaccination with vaccinia virus have been well described but are not commonly observed. The use of vaccinia as a tool in molecular biology, in the development of therapeutics, and the anticipated increase of vaccinations in the general population due to the threat of bioterrorism have created a renewed awareness of the post-vaccination complications and the consequent need for clinical and laboratory diagnosis.
OBJECTIVES: To report the clinical presentation and subsequent diagnosis of generalized vaccinia that resulted from a laboratory accident in an unvaccinated subject. STUDY
DESIGN: The patient was seen by a local infectious disease's specialist and evaluated clinically and with laboratory support relative to a differential diagnosis.
RESULTS: Careful assessment of the patient's history, an evaluation of the workplace, and the elimination of likely microbial etiologies led to the diagnosis of generalized vaccinia. Laboratory confirmation was obtained by use of electron microscopy (EM) to observe poxvirus particles in infected cell cultures.
CONCLUSIONS: Exposure to vaccinia virus should raise the index of suspicion for patients with skin lesions. Rapid diagnosis may be accomplished by direct examination of lesion material by EM. The virus also readily replicates in commonly available cell cultures and in the absence of immune reagents, typical poxvirus particles may be observed in the infected cells by EM.

Entities:  

Mesh:

Year:  2004        PMID: 14962785     DOI: 10.1016/S1386-6532(03)00118-5

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  8 in total

Review 1.  Evidence-based biosafety: a review of the principles and effectiveness of microbiological containment measures.

Authors:  Tjeerd G Kimman; Eric Smit; Michèl R Klein
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

2.  Poxvirus Protein MC132 from Molluscum Contagiosum Virus Inhibits NF-B Activation by Targeting p65 for Degradation.

Authors:  Gareth Brady; Darya A Haas; Paul J Farrell; Andreas Pichlmair; Andrew G Bowie
Journal:  J Virol       Date:  2015-08       Impact factor: 5.103

3.  Orthopox Viruses: Infections in Humans.

Authors:  Georg Pauli; Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen; Carl-Heinz Wirsing von König
Journal:  Transfus Med Hemother       Date:  2010-11-17       Impact factor: 3.747

4.  Comparison of methods for detection of vaccinia virus in patient specimens.

Authors:  Daniel P Fedorko; Jeanne C Preuss; Gary A Fahle; Li Li; Steven H Fischer; Patricia Hohman; Jeffrey I Cohen
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

5.  Molluscum Contagiosum Virus Protein MC005 Inhibits NF-κB Activation by Targeting NEMO-Regulated IκB Kinase Activation.

Authors:  Gareth Brady; Darya A Haas; Paul J Farrell; Andreas Pichlmair; Andrew G Bowie
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

6.  Can vaccinia virus be replaced by MVA virus for testing virucidal activity of chemical disinfectants?

Authors:  Holger F Rabenau; Ingrid Rapp; Jochen Steinmann
Journal:  BMC Infect Dis       Date:  2010-06-23       Impact factor: 3.090

7.  Ocular vaccinia infection in laboratory worker, Philadelphia, 2004.

Authors:  Felicia M T Lewis; Esther Chernak; Erinn Goldman; Yu Li; Kevin Karem; Inger K Damon; Richard Henkel; E Claire Newbern; Patrina Ross; Caroline C Johnson
Journal:  Emerg Infect Dis       Date:  2006-01       Impact factor: 6.883

8.  Genomic identification of human vaccinia virus keratoconjunctivitis and its importance as a laboratory-acquired infection.

Authors:  Zahra Movahedi Motlagh; Azam Mokhtari; Mohammadreza Mahzounieh
Journal:  Indian J Ophthalmol       Date:  2016-11       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.